---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-106398"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:16:54.414548+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Relmada prices $100M underwritten offering of common stock and pre-funded warrants at $2.20/share

## Summary
- Priced 40.1M shares of common stock at $2.20/share and pre-funded warrants for 5.3M shares at $2.199/warrant.
- Gross proceeds of ~$100M; net proceeds ~$100M after expenses, expected closing Nov 5, 2025.
- Investors include Janus Henderson, Ferring Ventures, Squadron Capital, Marshall Wace, Spruce Street, OrbiMed, Columbia Threadneedle, Driehaus.
- Company insiders (CEO, CFO, board members) purchasing ~$2.6M in shares at same price.
- Proceeds for working capital, clinical studies, product development, and potential acquisitions.

## SEC filing metadata
- accession: 0001213900-25-106398
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390025106398/0001213900-25-106398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390025106398/ea0263855-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-106398
- JSON: https://secwatch.observer/filing/0001213900-25-106398.json
- Plain text: https://secwatch.observer/filing/0001213900-25-106398.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.